Denali Therapeutics Inc. Accrued Liabilities, Current
Denali Therapeutics Inc. (DNLI) had Accrued Liabilities, Current of $78.28 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $78.28M.
- 2026-03-31: Accrued Liabilities, Current $69.78M.
- 2025-12-31: Accrued Liabilities, Current $97.85M; Accrued Liabilities, Current as first filed $95.02M.
- 2025-09-30: Accrued Liabilities, Current $4.94M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $78.28M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $69.78M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $97.85M 10-Q · filed 2026-08-06 | $95.02M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.94M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $7.01M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $7.35M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $91.07M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $4.83M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $6.01M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $5.99M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $68.50M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $66.69M 10-K · filed 2024-02-28 | |
| 2021-03-31 | $8.30M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $8.31M 10-Q · filed 2021-05-05 | |
| 2020-09-30 | $11.53M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $8.42M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $7.26M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $6.57M 10-Q · filed 2020-11-05 | |
| 2019-09-30 | $15.47M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $13.79M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $12.11M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $8.52M 10-Q · filed 2019-11-06 | |
| 2018-09-30 | $7.39M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $5.54M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $4.42M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $5.36M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |